Ticagrelor D7
| Product Name | Ticagrelor D7 |
|---|---|
| Alternate Names | Ticagrelor Stable Isotopes, Stable Isotopes of Ticagrelor |
| CAT No. | CS-O-07009 |
| CAS No. | 1265911-55-4 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 529.61 g/mol |
| Mol. For. | C₂₃H₂₁D₇F₂N₆O₄S |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Ticagrelor |
| Purity | Not less than 95 % |
| Therapeutic | Anti-Thrombotics |
| Smileys | FC1=C(F)C=CC([C@H]2[C@@H](C2)NC3=C(N=NN4[C@@H]5C[C@H](OCCO)[C@@H](O)[C@H]5O)C4=NC(SC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=N3)=C1 |
| Canonical Smiles | CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F |
| InchIKey | OEKWJQXRCDYSHL-MHTCSOGVSA-N |
| Inchl | InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1/i1D3,2D2,7D2 |
| IUPAC | (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(1,1,2,2,3,3,3-heptadeuteriopropylsulfanyl)triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Ticagrelor is an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome (ACS) and other conditions that increase the risk of heart attacks. Ticagrelor D7 is a deuterated form of Ticagrelor, which means that some hydrogen atoms in the molecular structure of the drug are replaced with deuterium atoms. This modification makes the drug more stable and increases its bioavailability, which can lead to more effective and consistent therapeutic outcomes.
Ticagrelor D7 works by blocking the P2Y12 receptor on platelets, which prevents them from aggregating and forming blood clots. This mechanism of action makes Ticagrelor D7 an important medication for patients who have undergone stent placement or who are at high risk for cardiovascular events.
The chemical formula of Ticagrelor D7 is C23H14D7F2N6O4S, and its molecular weight is 530.62 g/mol. The drug is administered orally as a tablet, and its recommended dosage is 90 mg twice daily for up to 12 months, depending on the patient's condition and response to treatment.
Like all medications, Ticagrelor D7 may cause side effects, including bleeding, shortness of breath, headache, and nausea. Patients taking Ticagrelor D7 should be closely monitored for signs of bleeding and other adverse reactions.
In conclusion, Ticagrelor D7 is a potent antiplatelet medication used to prevent blood clots in patients with ACS and other cardiovascular conditions. Its deuterated form enhances its stability and bioavailability, making it an effective and reliable treatment option for these patients.
Get an Instant Quote
Related Compounds
Desethoxyhydroxy Ticagrelor-d7 | Ticagrelor D4 | Ticagrelor metabolite-M8 D7 | Ticagrelor Metabolite-M5 D7 | Deshydroxyethoxy-2,3-O-(dimethylmethylene) Ticagrelor-d7 |